Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Dermatologic 2Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Peritoneal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × volociximab × Gynecologic × Clear all
NCT00635193 2013-01-18

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

AbbVie

Phase 1/2 Completed
138 enrolled
Gynecologic

Ovarian Neoplasms

NCT00516841 2012-08-23

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Facet Biotech

Phase 2 Terminated
16 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡